Published April 15, 2026 · Parkinson's Lawsuit Help
The paraquat Parkinson's litigation entered 2026 with more momentum than at any point in its history. Federal paraquat Parkinson's cases are consolidated in Multidistrict Litigation No. 3004, In re: Paraquat Products Liability Litigation, before Chief Judge Nancy J. Rosenstengel in the Southern District of Illinois. Thousands of cases are pending. A parallel mass tort program operates in the Philadelphia Court of Common Pleas before Judge Joshua Roberts, currently hosting approximately 1,799 active paraquat cases. In April 2025 Syngenta announced a settlement framework covering a substantial portion of the U.S. inventory; in January 2026 the first Philadelphia bellwether case settled confidentially on the courthouse steps. In March 2026 Syngenta announced it would discontinue U.S. production of paraquat. Below is a working snapshot of where claims stand, what changed in the last twelve months, and what claimants and family members should be paying attention to right now.
MDL 3004: where the federal docket stands
Multidistrict Litigation No. 3004 in the Southern District of Illinois continues to be the federal hub for paraquat Parkinson's cases. Bellwether selection, Daubert rulings on causation, and the court's handling of expert reports have shaped the negotiating posture of both sides. The MDL is not a class action — each plaintiff retains an individual claim and an individual recovery — but coordinated pretrial proceedings give the litigation scale and consistency that lone state-court filings cannot.
Philadelphia state court mass tort
Pennsylvania state court claimants are widely expected to recover more, on average, than federal MDL claimants. Three reasons: (1) Pennsylvania's consent-by-registration jurisdiction law — upheld after the U.S. Supreme Court declined to hear Syngenta's challenge in October 2025 — permits suits in Pennsylvania even against foreign defendants who registered to do business in the state; (2) Philadelphia juries have a long track record of higher verdicts in pharmaceutical and toxic tort cases than typical federal MDL bellwethers; and (3) the Philadelphia Complex Litigation Center moves cases on a faster trial schedule than the MDL, which gives plaintiffs leverage in settlement negotiations. The mass tort program in the Philadelphia Court of Common Pleas is the largest non-MDL paraquat docket in the country and has become a focal point of national settlement strategy.
Syngenta settlement framework
In April 2025 Syngenta publicly announced a settlement framework for a substantial portion of pending paraquat claims. The framework does not extinguish liability for cases that opt out, and it does not bind Chevron, which distributed paraquat in the United States. Claimants should treat the framework as a floor, not a ceiling — particularly those with strong causation evidence and clean differential diagnoses.
January 2026 Philadelphia bellwether
The first Philadelphia bellwether case settled confidentially on the courthouse steps in January 2026. While the dollar figure is sealed, the timing — minutes before jury selection began — is itself evidence that Syngenta and its co-defendants do not want a Pennsylvania jury verdict in a paraquat Parkinson's case on the books.
Syngenta discontinues U.S. paraquat production
In March 2026 Syngenta announced that it would discontinue U.S. production of paraquat. The company's framing emphasized commercial considerations; plaintiffs' counsel point to mounting litigation costs and reputational pressure. Either way, the discontinuation does not affect liability for past exposures.
What this means if you have a claim
If you or a family member were occupationally exposed to paraquat and have been diagnosed with Parkinson's disease, the practical takeaway is straightforward: do not wait. Settlement windows for global resolution programs typically close on tight schedules, and statutes of limitations continue to run regardless of where you file. A free case review takes a few minutes and locks in your place in the litigation while options remain open.
Get a free case review
If you or a family member were exposed to paraquat and have been diagnosed with Parkinson's disease, request a free case review. It takes 15 to 30 minutes by phone, costs nothing, and locks in your place while settlement options remain open. Check eligibility or call (717) 724-7503.